BCM
VRTX icon

Beck Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Beck Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,004
Closed -$932K – 130
2024
Q3 		$932K Buy
2,004
+38
+2% +$18.3K 0.25% 89
2024
Q2 		$922K Buy
1,966
+79
+4% +$34.3K 0.25% 86
2024
Q1 		$789K Buy
1,887
+3
+0.2% +$1.27K 0.23% 89
2023
Q4 		$767K Sell
1,884
-7
-0.4% -$2.59K 0.26% 88
2023
Q3 		$658K Buy
1,891
+21
+1% +$7.34K 0.25% 85
2023
Q2 		$658K Sell
1,870
-227
-11% -$76.5K 0.26% 87
2023
Q1 		$661K Sell
2,097
-132
-6% -$39.6K 0.28% 97
2022
Q4 		$644K Sell
2,229
-52
-2% -$15.8K 0.27% 106
2022
Q3 		$660K Buy
2,281
+43
+2% +$12.4K 0.28% 106
2022
Q2 		$631K Buy
+2,238
New +$599K 0.28% 98

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Beck Capital Management's VRTX Position: Q4 2024 in Review

Beck Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2024, closing a stake of 2,004 shares — an estimated $932K sold.

Beck Capital Management first reported a position in VRTX in Q2 2022 and held it in 10 quarters. The position peaked at $932K in Q3 2024. 1,557 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

  • Beck Capital Management reported no remaining Vertex Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Beck Capital Management sold 2,004 Vertex Pharmaceuticals shares in Q4 2024, an estimated $932K.
  • Beck Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2022 and held it in 10 quarters.
  • Beck Capital Management's Vertex Pharmaceuticals position peaked at $932K in Q3 2024.
  • 1,557 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on Beck Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.